Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (141-150 of 1,111) with videos related to

Pageof 112
Sort By:
Neurology|May 3, 2014
Influenza vaccination and cardiovascular risk in patients with recent TIA and strokePhilippa C Lavallée, Julien Labreuche, Kim M Fox, et al.
Archives of Cardiovascular Diseases|December 2, 2017
Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional studyFabien Picard, Gregory Ducrocq, Nicolas Danchin, et al.
Chest|August 11, 2004
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary EventsDavid Brieger, Kim A Eagle, Shaun G Goodman, et al.
American Heart Journal|January 28, 2010
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trialHarvey D White, Philip E Aylward, Richard Gallo, et al.
The American Journal of Cardiology|May 5, 2007
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry)Benjamin A Steinberg, P Gabriel Steg, Deepak L Bhatt, et al.
JAMA Internal Medicine|May 24, 2021
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical TrialXavier Mariette, Olivier Hermine, Pierre-Louis Tharaux, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|April 10, 2015
Heart rate and B-blockade in stable coronary artery disease in GreeceEftihia Sbarouni, Vassilis Voudris, Panagiota Georgiadou, et al.
Clinical Cardiology|October 10, 2013
Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF surveyJosé Silva-Cardoso, Oleg J Zharinov, Piotr Ponikowski, et al.
Journal of Clinical Lipidology|June 30, 2022
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-ITPrakriti Gaba, Deepak L Bhatt, R Preston Mason, et al.
Pageof 112

Showing results (141-150 of 1,111) with videos related to

Sort By:
Pageof 112
Neurology|May 3, 2014
Influenza vaccination and cardiovascular risk in patients with recent TIA and strokePhilippa C Lavallée, Julien Labreuche, Kim M Fox, et al.
Archives of Cardiovascular Diseases|December 2, 2017
Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional studyFabien Picard, Gregory Ducrocq, Nicolas Danchin, et al.
Chest|August 11, 2004
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary EventsDavid Brieger, Kim A Eagle, Shaun G Goodman, et al.
American Heart Journal|January 28, 2010
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trialHarvey D White, Philip E Aylward, Richard Gallo, et al.
The American Journal of Cardiology|May 5, 2007
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry)Benjamin A Steinberg, P Gabriel Steg, Deepak L Bhatt, et al.
JAMA Internal Medicine|May 24, 2021
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical TrialXavier Mariette, Olivier Hermine, Pierre-Louis Tharaux, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|April 10, 2015
Heart rate and B-blockade in stable coronary artery disease in GreeceEftihia Sbarouni, Vassilis Voudris, Panagiota Georgiadou, et al.
Clinical Cardiology|October 10, 2013
Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF surveyJosé Silva-Cardoso, Oleg J Zharinov, Piotr Ponikowski, et al.
Journal of Clinical Lipidology|June 30, 2022
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-ITPrakriti Gaba, Deepak L Bhatt, R Preston Mason, et al.
Pageof 112